Abbott Hits The Jackpot With Boston Scientific’s Acquisition Of Guidant
This article was originally published in The Gray Sheet
Executive Summary
Abbott stands poised to become a vascular and endovascular powerhouse should Boston Scientific's acquisition of Guidant clear Federal Trade Commission antitrust hurdles
You may also be interested in...
Abbott Vascular Prospects Aid 23% Stock Gain In 2006 – Index Up 5.7%
Abbott's and Johnson & Johnson's guidance to the device industry in 2006 was that diversification is key and some acquisitions are too good to pass up
Abbott Vascular Prospects Aid 23% Stock Gain In 2006 – Index Up 5.7%
Abbott's and Johnson & Johnson's guidance to the device industry in 2006 was that diversification is key and some acquisitions are too good to pass up
Boston Scientific, Guidant Close The Deal Following FTC Approval
Boston Scientific closed its $28 bil. acquisition of Guidant on April 21, one day after the Federal Trade Commission approved the deal - the largest medical device acquisition in history